BeiGene touts pos­i­tive PhI­II da­ta on tislelizum­ab in af­ter­math of set­backs at FDA

Af­ter the FDA in­def­i­nite­ly de­layed its de­ci­sion on BeiGene’s No­var­tis-part­nered PD-1 drug can­di­date tislelizum­ab as a monother­a­py for esophageal can­cer, No­var­tis an­nounced that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER